Ariana Pelosci

A dose-escalation schedule for neratinib may help some patients with HER2-positive breast cancer better manage severe diarrhea resulting from treatment.

Patients with KRAS-positive NSCLC being treated with rigosertib plus nivolumab demonstrated early efficacy of the combination in a phase 1/2a trial.

FoundationOne CDx, a comprehensive genomic profiling test, has been approved for use in conjunction with brigatinib to test for solid tumors in patients with ALK-positive NSCLC.

Patients with Wilms Tumor-1–positive ovarian cancer have shown promising response to the combination of galinpepimut-s and pembrolizumab.

Based on its potential to prolong overall survival in patients with glioblastoma multiforme, berubicin was granted fast track designation for the FDA for the treatment of recurrent disease.

Final overall survival results from TOURMALINE-MM1 failed to show statistical significance of an ixazomib combination for relapsed/refractory multiple myeloma overall.

Patients who discontinued endocrine therapy early were more likely to have experienced significant mental, physical, and social adverse effects of treatment.

The FDA granted orelabrutinib breakthrough therapy designation for the treatment of relapsed or refractory mantle cell lymphoma.

Patients in the ZUMA-7 trial who were assigned Yescarta (axicabtagene ciloleucel) saw event-free survival by 60% compared to patients who were on a chemotherapy plus stem cell regimen.

Patients with HCC who received atezolizumab/bevacizumab experienced a positive quality of life and improved disease symptoms vs sorafenib.

18FDG-PET was successful in identifying patients with HER2-positive early-stage breast cancer who were more likely to benefit from chemotherapy-free treatment with trastuzumab and pertuzumab.

The Oncologic Drugs Advisory Committee has decided to wait until more results from a clinical trial of retifanlimab are available to make a final decision about approval in squamous cell carcinoma of the anal canal.

Patients with long-term oropharyngeal cancer were surveyed regarding factors leading to severe effects on voice and speech.

STAR-OLZ has been found to significantly reduce adverse effects of chemotherapy-induced nausea and vomiting in clinical trials.

Individuals with an early-onset colorectal cancer diagnosis had a survival benefit versus those at later ages, especially for patients younger than 50 years old.

Targovax announced the FDA granted fast track designation to its investigational agent ONCOS-102 for PD-1–refractory advanced melanoma.

Bayer seeks FDA approval for its agent copanlisib in combination with rituximab for the treatment of patients with indolent non-Hodgkin lymphoma.

Differences in frequency of germline pathogenic variants were not seen in patient subsets by ethnicity when comparing 12 genes linked with breast cancer.

A trial of an eprenetapopt combination has met the prespecified primary efficacy end point in patients with acute myeloid leukemia harboring TP53 mutations.

Radioligand therapy 177Lu-PSMA-617 receives breakthrough designation from the FDA based on better overall survival outcomes in patients with metastatic castration-resistant prostate cancer.

Patients who had resection within 12 weeks of diagnosis of stage I NSCLC were found to have lower rates of recurrence.

Bemcentinib plus PD-1/L1 inhibition moves forward as therapy for patients with AXL-expressing non–small cell lung cancer.